Last Posted: Oct 15, 2019
- Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
Peters Brandilyn A et al. Genome medicine 2019 Oct (1) 61 - Resistance to Immune Checkpoint Blocker May Be Linked to Metabolic Imbalance
ASCO Post, October 10, 2019 - Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa Inês et al. Expert review of anticancer therapy 2017 Apr 17(4) 357-368 - Integrated genomic profiling expands clinical options for patients with cancer.
Beaubier Nike et al. Nature biotechnology 2019 Sep - Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.
Hsieh Jason Chia-Hsun et al. Head & neck 2019 Oct 41 Suppl 119-45 - Immunotherapy for heart injury
H Stover, Nature Medicine, October 7, 2019 - Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
Ancel Julien et al. Cancers 2019 Sep 11(10) - Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.
Popper Stephen J et al. The Journal of infectious diseases 2018 218(12) 1911-1921 - Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Johansson Peter A et al. Immunogenetics 2019 71(5-6) 433-436 - An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine.
Yamamoto Hiroyuki et al. Seminars in oncology 2019 Sep
.png)
No hay comentarios:
Publicar un comentario